385 related articles for article (PubMed ID: 23088786)
1. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
2. Anticancer activity of botanical alkyl hydroquinones attributed to topoisomerase II poisoning.
Huang CP; Fang WH; Lin LI; Chiou RY; Kan LS; Chi NH; Chen YR; Lin TY; Lin SB
Toxicol Appl Pharmacol; 2008 Mar; 227(3):331-8. PubMed ID: 18164362
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents.
Kamal A; Suresh P; Ramaiah MJ; Mallareddy A; Imthiajali S; Pushpavalli SN; Lavanya A; Pal-Bhadra M
Bioorg Med Chem; 2012 Mar; 20(6):2054-66. PubMed ID: 22364746
[TBL] [Abstract][Full Text] [Related]
4. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II.
Kawiak A; Piosik J; Stasilojc G; Gwizdek-Wisniewska A; Marczak L; Stobiecki M; Bigda J; Lojkowska E
Toxicol Appl Pharmacol; 2007 Sep; 223(3):267-76. PubMed ID: 17618663
[TBL] [Abstract][Full Text] [Related]
6. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
8. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
9. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
10. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
11. Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
Du L; Liu HC; Fu W; Li DH; Pan QM; Zhu TJ; Geng MY; Gu QQ
J Med Chem; 2011 Aug; 54(16):5796-810. PubMed ID: 21761866
[TBL] [Abstract][Full Text] [Related]
12. QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.
Chen MC; Pan SL; Shi Q; Xiao Z; Lee KH; Li TK; Teng CM
Cancer Sci; 2012 Jan; 103(1):80-7. PubMed ID: 21920000
[TBL] [Abstract][Full Text] [Related]
13. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
16. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
17. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.
Chikamori K; Hill JE; Grabowski DR; Zarkhin E; Grozav AG; Vaziri SA; Wang J; Gudkov AV; Rybicki LR; Bukowski RM; Yen A; Tanimoto M; Ganapathi MK; Ganapathi R
Leukemia; 2006 Oct; 20(10):1809-18. PubMed ID: 16932348
[TBL] [Abstract][Full Text] [Related]
19. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
[TBL] [Abstract][Full Text] [Related]
20. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex.
Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T
Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]